These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
147 related articles for article (PubMed ID: 1727735)
21. Relative contributions of advanced glycation and nitric oxide synthase inhibition to aminoguanidine-mediated renoprotection in diabetic rats. Soulis T; Cooper ME; Sastra S; Thallas V; Panagiotopoulos S; Bjerrum OJ; Jerums G Diabetologia; 1997 Oct; 40(10):1141-51. PubMed ID: 9349594 [TBL] [Abstract][Full Text] [Related]
22. Aminoguanidine pyridoxal adduct is superior to aminoguanidine for preventing diabetic nephropathy in mice. Miyoshi H; Taguchi T; Sugiura M; Takeuchi M; Yanagisawa K; Watanabe Y; Miwa I; Makita Z; Koike T Horm Metab Res; 2002 Jul; 34(7):371-7. PubMed ID: 12189584 [TBL] [Abstract][Full Text] [Related]
23. Potential benefit of inhibitors of advanced glycation end products in the progression of type II diabetes: a study with aminoguanidine in C57/BLKsJ diabetic mice. Piercy V; Toseland CD; Turner NC Metabolism; 1998 Dec; 47(12):1477-80. PubMed ID: 9867077 [TBL] [Abstract][Full Text] [Related]
24. Advanced glycosylation end-products in experimental murine diabetic nephropathy: effect of islet isografting and of aminoguanidine. Nicholls K; Mandel TE Lab Invest; 1989 Apr; 60(4):486-91. PubMed ID: 2496273 [TBL] [Abstract][Full Text] [Related]
25. Inhibition of endothelial cell differentiation on a glycosylated reconstituted basement membrane complex. Kuzuya M; Satake S; Miura H; Hayashi T; Iguchi A Exp Cell Res; 1996 Aug; 226(2):336-45. PubMed ID: 8806437 [TBL] [Abstract][Full Text] [Related]
26. Advanced glycation end products in vitreous: Structural and functional implications for diabetic vitreopathy. Stitt AW; Moore JE; Sharkey JA; Murphy G; Simpson DA; Bucala R; Vlassara H; Archer DB Invest Ophthalmol Vis Sci; 1998 Dec; 39(13):2517-23. PubMed ID: 9856760 [TBL] [Abstract][Full Text] [Related]
27. Advanced glycosylated end products and hyperglycemia in the pathogenesis of diabetic complications. Friedman EA Diabetes Care; 1999 Mar; 22 Suppl 2():B65-71. PubMed ID: 10097902 [TBL] [Abstract][Full Text] [Related]
28. Aminoguanidine inhibits oxidative modification of low density lipoprotein protein and the subsequent increase in uptake by macrophage scavenger receptors. Picard S; Parthasarathy S; Fruebis J; Witztum JL Proc Natl Acad Sci U S A; 1992 Aug; 89(15):6876-80. PubMed ID: 1495978 [TBL] [Abstract][Full Text] [Related]
29. Alterations in venous endothelial cell and smooth muscle cell relaxation induced by high glucose concentrations can be prevented by aminoguanidine. Davies MG; Hagen PO J Surg Res; 1996 Jul; 63(2):474-9. PubMed ID: 8661245 [TBL] [Abstract][Full Text] [Related]
30. Quercetin as a finer substitute to aminoguanidine in the inhibition of glycation products. Ashraf JM; Shahab U; Tabrez S; Lee EJ; Choi I; Ahmad S Int J Biol Macromol; 2015; 77():188-92. PubMed ID: 25799884 [TBL] [Abstract][Full Text] [Related]
31. The effectiveness of putative anti-cataract agents in the prevention of protein glycation. Stevens A J Am Optom Assoc; 1995 Dec; 66(12):744-9. PubMed ID: 8557952 [TBL] [Abstract][Full Text] [Related]
32. Resorcylidene aminoguanidine induces antithrombotic action that is not dependent on its antiglycation activity. Watala C; Dobaczewski M; Kazmierczak P; Gebicki J; Nocun M; Zitnanova I; Ulicna O; Durackova Z; Waczulíková I; Carsky J; Chlopicki S Vascul Pharmacol; 2009 Oct; 51(4):275-83. PubMed ID: 19635586 [TBL] [Abstract][Full Text] [Related]
33. Effect of chronic aminoguanidine treatment on age-related glycation, glycoxidation, and collagen cross-linking in the Fischer 344 rat. Sell DR; Nelson JF; Monnier VM J Gerontol A Biol Sci Med Sci; 2001 Sep; 56(9):B405-11. PubMed ID: 11524442 [TBL] [Abstract][Full Text] [Related]
34. Characterization of protein glycosylation using chip-based infusion nanoelectrospray linear ion trap tandem mass spectrometry. Zhang S; Chelius D J Biomol Tech; 2004 Jun; 15(2):120-33. PubMed ID: 15190085 [TBL] [Abstract][Full Text] [Related]
35. Kavalactones, a novel class of protein glycation and lipid peroxidation inhibitors. Upadhyay A; Tuenter E; Ahmad R; Amin A; Exarchou V; Apers S; Hermans N; Pieters L Planta Med; 2014 Aug; 80(12):1001-8. PubMed ID: 25098935 [TBL] [Abstract][Full Text] [Related]
36. Depletion of nitric oxide synthase-containing neurons in the diabetic retina: reversal by aminoguanidine. Roufail E; Soulis T; Boel E; Cooper ME; Rees S Diabetologia; 1998 Dec; 41(12):1419-25. PubMed ID: 9867208 [TBL] [Abstract][Full Text] [Related]
37. Effective inhibition of protein glycation by combinatorial usage of limonene and aminoguanidine through differential and synergistic mechanisms. Joglekar MM; Bavkar LN; Sistla S; Arvindekar AU Int J Biol Macromol; 2017 Jun; 99():563-569. PubMed ID: 28274869 [TBL] [Abstract][Full Text] [Related]
38. [Aminoguanidine suppresses methylglyoxal-mediated oxygen-glucose deprivation injury in human brain microvascular endothelial cells]. Li W; Hu Q; Ren X; He P; Xu H; Dai H; Chen Z Zhejiang Da Xue Xue Bao Yi Xue Ban; 2013 May; 42(3):261-6. PubMed ID: 23801613 [TBL] [Abstract][Full Text] [Related]
40. Long-term effects of aminoguanidine on insulin release and biosynthesis: evidence that the formation of advanced glycosylation end products inhibits B cell function. Tajiri Y; Möller C; Grill V Endocrinology; 1997 Jan; 138(1):273-80. PubMed ID: 8977414 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]